Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
Select Drug Profiles
,
Payers' Guide
Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Eylea (Aflibercept) Receives FDA Approval of New Dose for Age-Related Macular Degeneration
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
FDA Approvals of Novel Brand-Name Prescription Drugs in 2018
Read More
Select Drug Profiles
,
Payers' Guide
Ilumya (Tildrakizumab-asmn), Interleukin-23 Antagonist, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination FDA Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
,
Oncology Overview
,
Payers' Guide
New Indications Approved by the FDA in 2018 for Oncology Drugs
Dalia Buffery, MA, ABD
Read More
Select Drug Profiles
,
Payers' Guide
Nuzyra (Omadacycline) Approved for the Treatment of Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections
Loretta Fala
Read More
1
2
3
4
Page 1 of 19
Results 1 - 10 of 185